Ruxolitinib is a novel potent biologic agent that inhibits Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2), reserved for patients with myeloproliferative diseases [1]. Here, JAK2 is linked to myeloproliferative disorder.